<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00186420</url>
  </required_header>
  <id_info>
    <org_study_id>PROS0004</org_study_id>
    <nct_id>NCT00186420</nct_id>
  </id_info>
  <brief_title>Adjuvant Taxotere in Patients With High Risk Prostate Cancer Post Prostatectomy and Radiation</brief_title>
  <official_title>Adjuvant Taxotere in Patients With High Risk Prostate Cancer Post Prostatectomy and Radiation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aventis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate time to progression (TTP) by PSA in patients with
      high risk prostate cancer after definitive therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">January 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate time to progression (TTP) by PSA in patients with high risk prostate cancer after definitive therapy.</measure>
    <time_frame>Following treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the toxicity of taxotere and hormones given adjuvantly.</measure>
    <time_frame>Following treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To measure Quality of Life on this therapy.</measure>
    <time_frame>Following treatment</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">13</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Taxotere</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who have undergone a radical prostatectomy (should have unmeasurable PSA) or
             radiation therapy for prostate cancer and who have high risk disease as defined by one
             of the following:

               -  Node positive disease post-operatively

               -  Capsule involvement

               -  Seminal Vesicles involvement

               -  Gleason score ≥ 8

               -  &gt;50% of core biopsies that are positive

               -  Clinical Stage T2c and T3

               -  Pre-op PSA &gt; 15 plus Gleason score of 7

                    -  Age greater than 18

                    -  ECOG Performance Status 0-1

                    -  Serum creatinine &lt;= 1.5 mg/dl

                    -  Granulocyte count &gt;= 1500/m3, Hemoglobin &gt; 8.0 g/dl, and platelet count &gt;=
                       100,000/m3

                    -  Total bilirubin &lt;= ULN

                    -  AST, ALT and Alkaline Phosphatase must be within the range allowing for
                       eligibility.

                    -  Signed patient informed consent.

                    -  Men of childbearing potential must be willing to consent to using effective
                       contraception while on treatment and for three months thereafter.

        Exclusion Criteria:

          -  Peripheral neuropathy &gt; grade 1

          -  History of severe hypersensitivity to Taxotere® or other drugs formulated with
             polysorbate 80.

          -  Patients who have received previous chemotherapy or are being treated on another
             clinical trial using an investigational agent.

          -  Active infection within 14 days of beginning treatment

          -  Patients with a serious illness or medical condition, history of significant
             neurologic or psychiatric or active infection.

          -  Patients with a current malignancy. Patients with prior a history of in situ lobular
             carcinoma of the breast, basal or squamous cell skin cancer, are eligible.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandy Srinivas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University Cancer Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>June 12, 2012</last_update_submitted>
  <last_update_submitted_qc>June 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Sandy Srinivas</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>Taxotere</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

